A Phase 1 interventional study of PF-06882961 20MG in Hepatic Impairment and Healthy Volunteers, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-21.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma Pharmacokinetic (PK) of PF-06882961
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
≥6.5%; FPG ≥126 mg/Dl; \<60 mL/min/1.73m2;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm includes participants who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1
Drug: PF-06882961 20MG
This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
Drug: PF-06882961 20MG
This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
Drug: PF-06882961 20MG
This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
Drug: PF-06882961 20MG
PF-06882961 in 20 mg oral tablet will be administered on Day 1
Maximum Plasma Concentration (Cmax)
Maximum observed plasma PF-06882961 concentration.
Time frame: Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 and 48 hours post dose on Day 1.
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf)
Area under the plasma PF-06882961 concentration-time profile from time 0 extrapolated to infinite time.
Time frame: Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 and 48 hours post dose on Day 1.
Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)
Area under the plasma PF-06882961 concentration-time profile from time 0 extrapolated to the time of the last quantifiable concentration.
Time frame: Predose (0 hours), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 and 48 hours post dose on Day 1.
Fraction of Unbound Drug in Plasma (fu)
fu = Cu/C (where Cu represents unbound concentration and C represents total concentration).
Time frame: Predose (0 hours), and 4 hours post dose on Day 1.
Number of Participants Reporting Treatment-emergent Adverse Events (AEs)
Adverse events (AEs): any untoward medical occurrence in a clinical investigation participant administered a product or medical device, without regard to causality. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. AEs included SAEs and non-serious AEs. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). Treatment-related TEAEs were any untoward medical occurrence attributed to study treatment. Relatedness to study treatment was determined by the investigator.
Time frame: Baseline to Day 30
Number of Participants With Clinical Laboratory Abnormalities
Protocol-required safety laboratory assessments included: hemoglobin \<0.8 x lower limit of normal (LLN), hematocrit \<0.8 x LLN, erythrocytes \<0.8 x LLN, ery. mean corpuscular volume \>1.1 x upper limit of normal (ULN), ery. mean corpuscular hemoglobin \>1.1 x ULN, platelets \<0.5 x LLN, eosinophils \>1.2 x ULN, activated partial thromboplastin time \>1.1 x ULN, prothrombin time \>1.1 x ULN, prothrombin intl. normalized ratio \>1.1 x ULN; bilirubin/direct bilirubin/indirect bilirubin \>1.5 x ULN, aspartate aminotransferase/alanine aminotransferase/gamma glutamyl transferase \>3.0 x ULN, albumin \<0.8 x LLN, urate \>1.2 x ULN, bicarbonate \>1.1 x ULN, triacylglycerol lipase \>1.5 x ULN; urine hemoglobin/urine urobilinogen/urine nitrite/urine leukocyte esterase ≥1.
Time frame: Baseline to Day 3
Number of Participants With Categorical Vital Signs Data
Vital signs categorical criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (≥) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP ≥ 20 mmHg.
Time frame: Baseline to Day 3
Number of Participants With Categorical Electrocardiogram (ECG) Data
ECG categorical criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (≥) 300 millisecond (msec), b) ≥25% increase when baseline is \> 200 msec or ≥50% increase when baseline is less than or equal to (≤) 200 msec. 2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) ≥140 msec, b) ≥50% increase from baseline. 3. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and ≤480 msec, b) \>480 msec and ≤500 msec, c) \>500 msec, d) \>30 msec and ≤60 msec increase from baseline, e) \>60 msec increase from baseline
Time frame: Baseline to Day 3
| Milestone | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
Maximum observed plasma PF-06882961 concentration.
| nanogram per milliliter (ng/mL) | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) | 23.56 ± 50 | 31.37 ± 33 | 51.82 ± 83 | 78.73 ± 33 |
Area under the plasma PF-06882961 concentration-time profile from time 0 extrapolated to infinite time.
| nanogram*hour per milliliter (ng*hr/mL) | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) | 193.4 ± 83 | 237.3 ± 34 | 546.7 ± 116 | 1239 ± 75 |
Area under the plasma PF-06882961 concentration-time profile from time 0 extrapolated to the time of the last quantifiable concentration.
| nanogram*hour per milliliter (ng*hr/mL) | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) | 191.2 ± 84 | 235.0 ± 34 | 542.9 ± 117 | 1217 ± 73 |
fu = Cu/C (where Cu represents unbound concentration and C represents total concentration).
| Ratio | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Fraction of Unbound Drug in Plasma (fu) | 0.02137 ± 18 | 0.01820 ± 13 | 0.02059 ± 21 | 0.02889 ± 53 |
Adverse events (AEs): any untoward medical occurrence in a clinical investigation participant administered a product or medical device, without regard to causality. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. AEs included SAEs and non-serious AEs. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). Treatment-related TEAEs were any untoward medical occurrence attributed to study treatment. Relatedness to study treatment was determined by the investigator.
| Participants | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| All-causality | 0 | 1 | 2 | 1 |
| Treatment-related | 0 | 1 | 2 | 1 |
Protocol-required safety laboratory assessments included: hemoglobin \<0.8 x lower limit of normal (LLN), hematocrit \<0.8 x LLN, erythrocytes \<0.8 x LLN, ery. mean corpuscular volume \>1.1 x upper limit of normal (ULN), ery. mean corpuscular hemoglobin \>1.1 x ULN, platelets \<0.5 x LLN, eosinophils \>1.2 x ULN, activated partial thromboplastin time \>1.1 x ULN, prothrombin time \>1.1 x ULN, prothrombin intl. normalized ratio \>1.1 x ULN; bilirubin/direct bilirubin/indirect bilirubin \>1.5 x ULN, aspartate aminotransferase/alanine aminotransferase/gamma glutamyl transferase \>3.0 x ULN, albumin \<0.8 x LLN, urate \>1.2 x ULN, bicarbonate \>1.1 x ULN, triacylglycerol lipase \>1.5 x ULN; urine hemoglobin/urine urobilinogen/urine nitrite/urine leukocyte esterase ≥1.
| Participants | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Number of Participants With Clinical Laboratory Abnormalities | 3 | 4 | 5 | 6 |
Vital signs categorical criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (≥) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP ≥ 20 mmHg.
| Participants | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Pulse rate value <40 bpm | 0 | 0 | 0 | 0 |
| Pulse rate value >120 bpm | 0 | 0 | 0 | 0 |
| Sitting DBP value <50 mm Hg | 0 | 0 | 0 | 1 |
| Sitting DBP Change ≥ 20 mm Hg increase | 0 | 0 | 2 | 1 |
| Sitting DBP Change ≥ 20 mm Hg decrease | 0 | 0 | 0 | 0 |
| Sitting SBP value <90 mm Hg | 0 | 0 | 0 | 1 |
| Sitting SBP Change ≥ 30 mm Hg increase | 1 | 0 | 0 | 0 |
| Sitting SBP Change ≥ 30 mm Hg decrease | 0 | 0 | 0 | 0 |
ECG categorical criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (≥) 300 millisecond (msec), b) ≥25% increase when baseline is \> 200 msec or ≥50% increase when baseline is less than or equal to (≤) 200 msec. 2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) ≥140 msec, b) ≥50% increase from baseline. 3. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and ≤480 msec, b) \>480 msec and ≤500 msec, c) \>500 msec, d) \>30 msec and ≤60 msec increase from baseline, e) \>60 msec increase from baseline
| Participants | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| PR interval ≥300 msec | 0 | 0 | 0 | 0 |
| %Change in PR interval ≥25/50% | 0 | 0 | 0 | 1 |
| QRS interval ≥140 msec | 0 | 0 | 0 | 0 |
| %Change in QRS interval ≥50% | 0 | 0 | 0 | 0 |
| QTcF interval >450 and ≤480 msec | 0 | 1 | 1 | 3 |
| QTcF interval >480 and ≤500 msec | 0 | 0 | 0 | 0 |
| QTcF interval >500 msec | 0 | 0 | 0 | 0 |
| Change in QTcF interval >30 and ≤60 msec | 0 | 0 | 0 | 0 |
| Change in QTcF interval >60 msec | 0 | 0 | 0 | 0 |
Collected over Baseline to Day 30. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Without Hepatic Impairment | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Mild Hepatic Impairment | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Moderate Hepatic Impairment | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Severe Hepatic Impairment | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Event | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 2/6 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 0/6 |
| VomitingGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 |
The baseline analysis population included all participants enrolled in the study.
| Age, Continuous(Years) | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| Mean | 59.3 ± 3.08 | 61.7 ± 5.85 | 57.7 ± 7.12 | 56.2 ± 10.21 | 58.7 ± 6.89 |
| Age, Customized(Participants) | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| 45-64 Years | 6 | 3 | 5 | 4 | 18 |
| >=65 Years | 0 | 3 | 1 | 2 | 6 |
| Sex: Female, Male(Participants) | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| Female | 3 | 2 | 3 | 3 | 11 |
| Male | 3 | 4 | 3 | 3 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 3 | 3 | 13 |
| Not Hispanic or Latino | 2 | 3 | 3 | 3 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Without Hepatic Impairment | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| White | 6 | 5 | 6 | 5 | 22 |
| Black or African American | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Dec 2020 to primary completion in Jan 2022, 12 months.
Results were first posted in Mar 2024, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Danuglipron